Genentech Bets on Bicycle-Based Therapies

Genentech Bets on Bicycle-Based Therapies

by | Mar 2, 2020 12:29 pm | Biotechnology

Genentech, a subsidiary of the Roche Group (OTCMKTS: RHHBY), is betting big on a collaboration effort with Bicycle Therapeutics plc (NASDAQ: BCYC). The exclusive collaboration agreement between the two biotechnology companies hopes to develop and commercialize Bicycle-based immuno-oncology therapies against multiple targets. Genetech will pay $30 million upfront to Bicycle Therapeutics with a potential $1.7 billion in milestone payments. You might have guessed this based on the name, but Bicycles are Bicycle Therapeutics’ trademark platform. They are fully synthetic short peptides constrained with small-molecule scaffolds to form two loops that stabilize their structural geometry.... Read More »
Biogen Eyes Two Ophthalmic Biosimilars

Biogen Eyes Two Ophthalmic Biosimilars

by | Nov 15, 2019 3:30 pm | Pharmaceuticals

Boston-based Biogen Inc. (NASDAQ: BIIB) has announced a “proposed transaction” with Samsung Bioepis Co., Ltd. to secure the exclusive rights to commercialize two new ophthalmology biosimilars, SB11 referencing Lucentis® and SB15 referencing Eylea®, in major markets worldwide, including the United States, Canada, Europe, Japan and Australia. In addition, Biogen will acquire exclusive commercialization rights for Samsung Bioepis’ anti-TNF portfolio, including Benepali (etanercept), Flixabi (infliximab) and Imraldi (adalimumab), in China. Biogen will also acquire an option to extend its existing commercial agreement with Samsung Bioepis for this anti-TNF portfolio in Europe.... Read More »
Roche Deal for Flatiron Health Builds its Oncology Muscle

Roche Deal for Flatiron Health Builds its Oncology Muscle

by | Feb 16, 2018 11:21 am | Biotechnology, eHealth

Roche (SIX: RO) couldn’t let a good startup slip away. The Swiss drug maker announced it will pay $1.9 billion to keep New York City-based Flatiron Health, Inc. from going public. When it was founded in 2012, Flatiron’s goal was to gather and analyze data on cancer treatments and sells software based on those insights to help researchers develop drugs more quickly, and with more targeted precision. Toward that end, the company produced an oncology-specific electronic health record (EHR). It currently partners with more than 265 community cancer clinics, six major academic research centers and 14 out of the top 15 therapeutic oncology companies. Roche already holds a 12.6% stake... Read More »